Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 2;4(3):otac030.
doi: 10.1093/crocol/otac030. eCollection 2022 Jul.

Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter Registry

Affiliations

Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter Registry

Edward L Barnes et al. Crohns Colitis 360. .

Abstract

Background: Much of our understanding about the natural history of pouch-related disorders has been generated from selected populations. We designed a geographically diverse, prospective registry to study the disease course among patients with 1 of 4 inflammatory conditions of the pouch. The primary objectives in this study were to demonstrate the feasibility of a prospective pouch registry and to evaluate the predominant treatment patterns for pouch-related disorders.

Methods: We used standardized diagnostic criteria to prospectively enroll patients with acute pouchitis, chronic antibiotic-dependent pouchitis (CADP), chronic antibiotic refractory pouchitis (CARP), or Crohn's disease (CD) of the pouch. We obtained detailed clinical and demographic data at the time of enrollment, along with patient-reported outcome (PRO) measures.

Results: We enrolled 318 patients (10% acute pouchitis, 27% CADP, 12% CARP, and 51% CD of the pouch). Among all patients, 55% were on a biologic or small molecule therapy. Patients with CD of the pouch were more likely to use several classes of therapy (P < .001). Among patients with active disease at the time of enrollment, 23% with CARP and 40% with CD of the pouch were in clinical remission at 6 months after enrollment.

Conclusions: In a population where most patients had refractory inflammatory conditions of the pouch, we established a framework to evaluate PROs and clinical effectiveness. This infrastructure will be valuable for long-term studies of real-world effectiveness for pouch-related disorders.

Keywords: Crohn’s disease of the pouch; ileal pouch-anal anastomosis; pouchitis; real-world effectiveness.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
FIGURE 1.
FIGURE 1.
Comparison of proportion of patients with Crohn’s disease of the pouch in clinical remission at 6 months after enrollment, stratified by disease activity at enrollment (remission vs active disease) and initial therapy. Abbreviation: anti-TNF, anti-tumor necrosis factor alpha. Only those patients with available data at 6 months presented.

References

    1. Devaraj B, Kaiser AM.. Surgical management of ulcerative colitis in the era of biologicals. Inflamm Bowel Dis. 2015;21:208–220. - PubMed
    1. Lightner AL, Mathis KL, Dozois EJ, et al. . Results at up to 30 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Inflamm Bowel Dis. 2017;23:781–790. - PubMed
    1. Fazio VW, Kiran RP, Remzi FH, et al. . Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013;257:679–685. - PubMed
    1. Barnes EL, Herfarth HH, Sandler RS, et al. . Pouch-related symptoms and quality of life in patients with ileal pouch-anal anastomosis. Inflamm Bowel Dis. 2017;23:1218–1224. - PMC - PubMed
    1. Barnes EL, Kochar B, Jessup HR, et al. . The incidence and definition of Crohn’s disease of the pouch: a systematic review and meta-analysis. Inflamm Bowel Dis. 2019;25:1474–1480. - PMC - PubMed